<DOC>
	<DOCNO>NCT02400359</DOCNO>
	<brief_summary>The purpose protocol investigate , use functional magnetic resonance imaging ( fMRI ) , effect treatment lorcaserin center brain control appetite food intake , well lorcaserin 's downstream metabolic effect .</brief_summary>
	<brief_title>Lorcaserin Obesity : Identification CNS Targets Using fMRI</brief_title>
	<detailed_description>The purpose protocol investigate effect treatment study drug , call lorcaserin center brain control appetite food intake , well lorcaserin 's metabolic effect . Lorcaserin 's effect brain investigate use functional magnetic resonance imaging ( fMRI ) . Lorcaserin approve June 2012 addition reduced-calorie diet exercise , chronic weight management . Previous weight loss drug , fenfluramine , act throughout body caused heart problem . Lorcaserin different act receptor ( site action ) find brain act heart , thus , show cause heart problem see past . 1 . To examine effect study drug lorcaserin , brain , impact food visualization ( high fat low fat image ) interaction satiety ( measure fast feed state ) use fMRI . ( Satiety define person enough much food want eat , finish satisfy meal . ) 2 . To examine satiety weight-reducing effect lorcaserin use physiological measurement ( much weight lose may affect hormone level ) , association change fMRI response neuropsychological performance . To examine whether long-term weight reduce effect lorcaserin predict early food visualization .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<criteria>Obese : BMI &gt; 30 kg/m2 &gt; 27 kg/m2 comorbidities ( include limit insulin resistance , hypertension , dyslipidemia , cardiovascular disease , stroke , sleep apnea , gallbladder disease , hyperuricemia gout , osteoarthritis ) . Additionally , woman participant must use double barrier method prevent pregnancy ( diaphragm intravaginal spermicide , cervical cap , male female condom spermicide ) . If woman suspect become pregnant time use one contraceptive method recommend investigator , must notify study staff . If woman become pregnant , withdrawn study . The study staff follow progress pregnancy birth child . 1 . Subjects use weight loss product ( orlistat , phentermine , topiramate , fenfluramine , dexfenfluramine , amphetamine , GLP1 agonists ) use within 3 month . 2 . Women breastfeed , pregnant , want become pregnant . 3 . Women use IUD ( intrauterine device ) 4 . Any change dosage hormonal contraceptive medication ( birth control pill , implanon ) . Subjects remain medication/ dose time entire study . 5 . Moderate ( creatinine clearance 3059 ml/min ) severe renal impairment ( creatinine clearance 30 ml/min ) endstage renal disease 6 . Moderate , severe hepatic impairment 7 . Hypersensitivity active substance excipients lorcaserin 8 . Congestive heart failure and/or pulmonary hypertension 9 . Arrhythmias ( bradycardia , tachycardia ) valvular heart diseases 10 . Diagnosis diabetes , define per ADA criterion Hba1c &gt; 6.5 % and/or fast glucose &gt; 125 mg/dL and/or random glucose &gt; 200 mg/dL 11 . Inflammatory condition like inflammatory bowel disease , Rheumatoid arthritis etc . 12 . Alcohol consumption maximum quantity men 140g—210g per week . For woman , range 84g—140g per week drink consume two drink day men one woman . Alcohol cause increase risk pancreatitis hypoglycemia . 13 . Untreated thyroid disease like hypothyroidism hyperthyroidism 14 . Subjects take following medication : phosphodiesterase inhibitor , serotonergic medication ( e.g . SSRI ( selective serotonin reuptake inhibitor ) , SNRI , MAO ( monoamine oxidase ) inhibitor , bupropion , tricyclic antidepressant , St. John 's Wort ) , valproic acid , codeine ( CYP2D6 inhibition ) , tamoxifen , timolol , warfarin , steroid ( inhaled systemic due reduce hypoglycemic effect ) , subject hormone ( LHRH analogs etc ) . 15 . Subjects type bioimplant activate mechanical , electronic , magnetic mean ( e.g . cochlear implant , pacemaker , neuron biostimulators , electronic infusion pump , etc . ) 16 . Subjects type metallic implant could potentially displace damaged MRI , aneurysm clip , metallic skull plate , surgical implant etc . metal contain tattoo 17 . Anxiety small space and/or claustrophobia 18 . Uncontrolled cardiac impairment , circulatory impairment , inability perspire ( poor thermoregulatory function ) 19 . Significant sensory motor impairment 20 . Epilepsy , particularly photosensitive epilepsy , may place individual high risk adverse event fMRI scan visual stimulation 21 . Subjects neurological problem may interfere complicate testing ( e.g . presence titubation ) 22 . Body weight limitation MRI scan table ( 330lbs/150 Kg ) body dimension could difficult performance scan . 23 . Subjects adhere experimental protocol reason 24 . Anemia Hgb less 10 25 . Uncontrolled infectious disease ( e.g . HIV , hepatitis , chronic infection etc ) 26 . Any uncontrolled endocrine condition , e.g . Cushing 's , Acromegaly , etc 27 . Any cancer lymphoma 28 . Eating disorder like anorexia , bulimia 29 . Weight loss surgery gastrectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>fMRI</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>endocrinology</keyword>
	<keyword>MRI</keyword>
	<keyword>obesity</keyword>
	<keyword>weight loss</keyword>
	<keyword>lorcaserin</keyword>
</DOC>